News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
This unique record was made possible by collating hard copies of the books in a structured manner
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
With the launch of QurOne, the brand aims to redefine healthcare in the country with seamless, hassle-free patient care and hyper-coordinated workflows
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
